The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer

Overview

Journal Gut Liver

Specialty Gastroenterology

Date 2016 Aug 27

PMID 27563018

Citations 11

Authors

Sunil Amin

Paolo Boffetta

Aimee L Lucas

Affiliations

Soon will be listed here.

Abstract

Survival from pancreatic cancer remains poor. Conventional treatment has resulted in only marginal improvements in survival compared with survival in the previous several decades. Thus, considerable interest has emerged regarding the potential use of common pharmaceutical agents as chemopreventative and chemotherapeutic options. Aspirin, metformin, statins, β-blockers, and bisphosphonates have biologically plausible mechanisms to inhibit pancreatic neoplasia, whereas dipeptidyl-peptidase 4 inhibitors may promote it. Regardless, real-world epidemiological data remain inconclusive. This review examines the hypotheses, evidence, and current state of the literature for each of these medications and their potential roles in the prevention and treatment of pancreatic cancer.

Citing Articles

An Update on Common Pharmaceuticals in the Prevention of Pancreatic Cancer.

Miyaki C, Lynch L Cureus. 2022; 14(5):e25496.

PMID: 35800820 PMC: 9246430. DOI: 10.7759/cureus.25496.

Chemopreventive Effects of Concomitant or Individual Use of Statins, Aspirin, Metformin, and Angiotensin Drugs: A Study Using Claims Data of 23 Million Individuals.

Wang C, Huang C, Nguyen P, Lin M, Yeh C, Islam M Cancers (Basel). 2022; 14(5).

PMID: 35267516 PMC: 8909564. DOI: 10.3390/cancers14051211.

Bisphosphonate Use Does Not Impact Survival in Patients with Pancreatic Cancer: A Propensity Score Matching Analysis.

Zylberberg H, Rustgi S, Yang A, Aronson A, Kessel E, Amin S Gut Liver. 2021; 15(5):782-790.

PMID: 34158422 PMC: 8444100. DOI: 10.5009/gnl20297.

Beta-blockers have no impact on survival in pancreatic ductal adenocarcinoma prior to cancer diagnosis.

Yang A, Zylberberg H, Rustgi S, Amin S, Bar-Mashiah A, Boffetta P Sci Rep. 2021; 11(1):1038.

PMID: 33441781 PMC: 7807087. DOI: 10.1038/s41598-020-79999-0.

Cancer Biology and Prevention in Diabetes.

Srivastava S, Goodwin J Cells. 2020; 9(6).

PMID: 32498358 PMC: 7349292. DOI: 10.3390/cells9061380.

References

Lee M, Hsu C, Wahlqvist M, Tsai H, Chang Y, Huang Y . Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011; 11:20. PMC: 3031263. DOI: 10.1186/1471-2407-11-20. View

Pasca di Magliano M, Logsdon C . Roles for KRAS in pancreatic tumor development and progression. Gastroenterology. 2013; 144(6):1220-9. PMC: 3902845. DOI: 10.1053/j.gastro.2013.01.071. View

Tella S, Rendell M . DPP-4 inhibitors: focus on safety. Expert Opin Drug Saf. 2014; 14(1):127-40. DOI: 10.1517/14740338.2015.977863. View

Monami M, Dicembrini I, Mannucci E . Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013; 16(1):48-56. DOI: 10.1111/dom.12176. View

Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M . Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988; 53(4):549-54. DOI: 10.1016/0092-8674(88)90571-5. View

Diel I, Solomayer E, Costa S, Gollan C, Goerner R, Wallwiener D . Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998; 339(6):357-63. DOI: 10.1056/NEJM199808063390601. View

Zhao M, Tominaga Y, Ohuchida K, Mizumoto K, Cui L, Kozono S . Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer. Cancer Sci. 2011; 103(1):58-66. PMC: 11164147. DOI: 10.1111/j.1349-7006.2011.02113.x. View

Cui X, He Q, Zhang J, Fan H, Wen Z, Qin Y . High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis. Pancreas. 2013; 43(1):135-40. DOI: 10.1097/MPA.0b013e3182a8d41f. View

Larsson S, Giovannucci E, Bergkvist L, Wolk A . Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006; 15(12):2561-4. DOI: 10.1158/1055-9965.EPI-06-0574. View

10.

Askari M, Tsao M, Schuller H . The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors. J Cancer Res Clin Oncol. 2005; 131(10):639-48. DOI: 10.1007/s00432-005-0002-7. View

11.

Cardwell C, Abnet C, Veal P, Hughes C, Cantwell M, Murray L . Exposure to oral bisphosphonates and risk of cancer. Int J Cancer. 2011; 131(5):E717-25. PMC: 3517893. DOI: 10.1002/ijc.27389. View

12.

Butler A, Campbell-Thompson M, Gurlo T, Dawson D, Atkinson M, Butler P . Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013; 62(7):2595-604. PMC: 3712065. DOI: 10.2337/db12-1686. View

13.

Khurana V, Sheth A, Caldito G, Barkin J . Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas. 2007; 34(2):260-5. DOI: 10.1097/MPA.0b013e318030e963. View

14.

Anderson K, Johnson T, Lazovich D, Folsom A . Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst. 2002; 94(15):1168-71. DOI: 10.1093/jnci/94.15.1168. View

15.

Watson J, Wise L, Green J . Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol. 2007; 63(9):843-9. DOI: 10.1007/s00228-007-0320-6. View

16.

Coogan P, Rosenberg L, Palmer J, Strom B, Zauber A, STOLLEY P . Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev. 2000; 9(1):119-23. View

17.

Sood A, Bhatty R, Kamat A, Landen C, Han L, Thaker P . Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 2006; 12(2):369-75. PMC: 3141061. DOI: 10.1158/1078-0432.CCR-05-1698. View

18.

Carey F, Little M, Pugh T, Ndokera R, Ing H, Clark A . The differential effects of statins on the risk of developing pancreatic cancer: a case-control study in two centres in the United Kingdom. Dig Dis Sci. 2013; 58(11):3308-12. DOI: 10.1007/s10620-013-2778-7. View

19.

Rothwell P, Fowkes F, Belch J, Ogawa H, Warlow C, Meade T . Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2010; 377(9759):31-41. DOI: 10.1016/S0140-6736(10)62110-1. View

20.

Vallianou N, Kostantinou A, Kougias M, Kazazis C . Statins and cancer. Anticancer Agents Med Chem. 2013; 14(5):706-12. DOI: 10.2174/1871520613666131129105035. View